IFNGamma Signature Not Linked to DurvalumabTremelimumab Benefit in Gastric Cancer

IFN-Gamma Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer

Geoffrey Y. Ku, MD, discusses data of durvalumab plus tremelimumab in a biomarker-selected patient population and sheds light on the role of immunotherapy in patients with advanced gastric cancer.

More From BioPortfolio on "IFN-Gamma Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer"